Psoriasis

Apremilast Therapeutic Cheat Sheet
apremilast
by Alexis Carrington, MD on
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …
JDD February 2023 Issue Highlights
by NEXT STEPS IN DERM TEAM on
The February issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and brief communications exploring topics such as efficacy and safety of 1% clascoterone cream in patients aged ≥12 years with acne vulgaris, dupilumab’s impact on atopic dermatitis among adolescent and adult patients, development and validation of a photonumeric scale …
Applying the Psoriasis Guidelines to Practice
psoriasis guidelines
by NEXT STEPS IN DERM TEAM on
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources,  interviewed Dr. April Armstrong (Professor of Dermatology and Associate Dean for Clinical Research at the Keck School of Medicine at USC) on applying the psoriasis guidelines established by the American Academy of Dermatology and the National Psor …
Skincare Mondays | Glycerin: The Unsung Hero of Skincare
Glycerin
by Johnson & Johnson Consumer Health on
DID YOU KNOW? Glycerin is among the most popular ingredients in beauty products, behind water and fragrance.1 With a 50+ year history of use, glycerin is a deceptively simple molecule classified as a powerful humectant that is anything but basic. Glycerin is recognized by the U.S. Food & Drug Administration (FDA) as an over-the-counter skin protectant when used between 20-45%.2 …
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
psoriasis
by NEXT STEPS IN DERM TEAM on
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of targeted biologic agents offers safe, effective options for children with moderate-to-severe skin and nail disease. A few are now Food and Drug Administration (FDA)-approved for children. INTRODUCTIO …